HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Raises Price Target to $125

Benzinga Newsdesk www.benzinga.com Positive 70.5%

Neg 0% Neu 0% Pos 70.5%

HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises the price target from $110 to $125.